BioSpace News Archive

Glioblastoma is the most aggressive type of primary brain cancer, one with a prognosis of 11-15 months with standard treatment. Results from a phase 1b clinical trial of a new experimental glioblastoma vaccine developed by Jefferson Health and Imvax, show the treatment was tolerated well by patients, slowed tumor recurrence, and prolonged patient survival.

CATHEXIS, a management consulting company that provides innovative enterprise performance improvement services to leading federal government clients, has won a contract to conduct medical invoice audits for the Veterans Benefits Administration (VBA) over the next five years.

Flash therapy preclinical results presented at AACR

Oncology professionals from all over the world met in Orlando to discuss how to better address the needs of people with cancer. Join the conversation online with the hashtag #NCCNac19

Sonendo announced the Canada launch of the GentleWave System.

Pharm-Olam was rated highly by small pharma survey respondents, as well as all survey respondents combined, for delivering excellent clinical research services in Compatibility, Quality, and Reliability core award categories.

AMX0035 is Amylyx’s proprietary two-drug combination therapy in development to prevent nerve cell death and degeneration.

ValGenesis, Inc., a leading provider of Validation Lifecycle Management System (VLMS) software solutions, today announced the availability of a mobile app for tablets with ValGenesis VLMS for iOS, Android and Microsoft tablets.

The human body houses trillions of microscopic organisms called microbes that collectively make up a microbiome.

As the largest and most comprehensive multi-specialty non-profit animal hospital in the world, these gifts ensure that AMC remains at the forefront of veterinary medicine and can continue to grow to meet client demand.